Advertisement

Health Economics for Neuropsychological Diseases in China

  • Hai-lun Cui
  • Gang WangEmail author
Living reference work entry

Abstract

As an important economy branch dealing with the allocation of health-related resource, health economics mainly covers studies concentrating on issues related to multiple medical actions and disease researches concerning efficiency, effectiveness, value, and behavior in the production and consumption of both health and health care. The focus of this chapter is to give a brief introduction on the notions and definitions of the modern health economies, as well as the general containment of the works underlying this specific notion of study. Two commonly seen neuropsychological or neurodegenerative diseases (Parkinson’s disease and Alzheimer’s disease), both inconvertible and with relatively lengthy process, are specifically described in order to illustrate the work of health economies in a well-understood manner. The calculation of the economic burden and the process of financial evaluation of the two examples would help demonstrate the importance of economic planning of health problems.

References

  1. Allegri RF, Butman J, Arizaga RL, Machnicki G, Serrano C, Taragano FE, Sarasola D, Lon L. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr. 2007;19(4):705–18.CrossRefGoogle Scholar
  2. Anderson GF, Chalkidou K. Spending on medical care: more is better? JAMA. 2008;299(20): 2444–5.CrossRefGoogle Scholar
  3. Bragaglia P, O’Brien L. Chronic disease management: the primary care perspective. Healthc Pap. 2007;7(4):26–8; discussion 68–70.CrossRefGoogle Scholar
  4. Dodel RC, Haacke C, Zamzow K, Paweilik S, Spottke A, Rethfeldt M, Siebert U, Oertel WH, Schoffski O, Back T. Resource utilization and costs of stroke unit care in Germany. Value Health. 2004;7(2):144–52.CrossRefGoogle Scholar
  5. Durrani H. Healthcare and healthcare systems: inspiring progress and future prospects. mHealth. 2016;2:3.PubMedPubMedCentralGoogle Scholar
  6. Fan VY, Savedoff WD. The health financing transition: a conceptual framework and empirical evidence. Soc Sci Med. 2014;105:112–21.CrossRefGoogle Scholar
  7. Fan J, Dawson TM, Dawson VL. Cell death mechanisms of neurodegeneration. Adv Neurobiol. 2017;15:403–25.CrossRefGoogle Scholar
  8. Garibaldi P, Martins JO, van Ours J. Ageing, health, and productivity: the economics of increased life expectancy. Oxford: Oxford University Press; 2010.CrossRefGoogle Scholar
  9. Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: a summary report and call to action. Ann Neurol. 2017;81(4):479–84.CrossRefGoogle Scholar
  10. Guerriere DN, Tranmer JE, Ungar WJ, Manoharan V, Coyte PC. Valuing care recipient and family caregiver time: A comparison of methods. International Journal of Technology Assessment in Health Care. 2008;24(01):52–9.CrossRefGoogle Scholar
  11. Hall RE, Jones CI. The value of life and the rise in health spending. Q J Econ. 2007;122(1):39–72.CrossRefGoogle Scholar
  12. Harrow BS, Mahoney DF, Mendelsohn AB, Ory MG, Coon DW, Belle SH, Nichols LO. Variation in cost of informal caregiving and formal-service use for people with Alzheimer’s desease. American Journal of Alzheimer’s Disease & Other Dementias. 2004;19(5):299–308.Google Scholar
  13. Jia J, Zhou A, Wei C, Jia X, Wang F, Li F, Wu X, Mok V, Gauthier S, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X. The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese. Alzheimers Dement. 2014;10(4):439–47.CrossRefGoogle Scholar
  14. Jonsson L, Eriksdotter Jonhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G, Nygaard H, Andreasen N, Winblad B, Wimo A. Determinants of costs of care for patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2006;21(5):449–59.CrossRefGoogle Scholar
  15. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013;28(3):311–8.CrossRefGoogle Scholar
  16. Langa KM, Larson EB, Crimmins EM, Faul JD, Levine DA, Kabeto MU, Weir DR. A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA Intern Med. 2017;177(1):51–8.CrossRefGoogle Scholar
  17. Liu N, Zhang J, Guo L. Alzheimer’s disease epidemiological situation. J Liaoning Univ Tradit Chin Med. 2011;1:35–6.Google Scholar
  18. Manes F. The huge burden of dementia in Latin America. Lancet Neurol. 2016;15(1):29.CrossRefGoogle Scholar
  19. Morris S, Patel N, Baio G, Kelly L, Lewis-Holmes E, Omar RZ, Katona C, Cooper C, Livingston G. Monetary costs of agitation in older adults with Alzheimer’s disease in the UK: prospective cohort study. BMJ Open. 2015;5(3):e007382.CrossRefGoogle Scholar
  20. Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson’s disease in Asia. J Epidemiol. 2009;19(6):281–93.CrossRefGoogle Scholar
  21. Park M, Sung M, Kim SK, Kim S, Lee DY. Multidimensional determinants of family caregiver burden in Alzheimer’s disease. Int Psychogeriatr. 2015;27(8):1355–64.CrossRefGoogle Scholar
  22. Prince M. Care arrangements for people with dementia in developing countries. Int J Geriatr Psychiatry. 2004;19(2):170–7.CrossRefGoogle Scholar
  23. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984;16(3):278–82.CrossRefGoogle Scholar
  24. Sorenson C, Drummond M, Bhuiyan Khan B. Medical technology as a key driver of rising health expenditure: disentangling the relationship. Clinicoecon Outcomes Res. 2013;5:223–34.CrossRefGoogle Scholar
  25. von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol. 2005;15(4):473–90.CrossRefGoogle Scholar
  26. Wang G, Cheng Q, Zheng R, Tan YY, Sun XK, Zhou HY, Ye XL, Wang Y, Wang Z, Sun BM, Chen SD. Economic burden of Parkinson’s disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord. 2006;21(9):1439–43.CrossRefGoogle Scholar
  27. Wang G, Cheng Q, Zhang S, Bai L, Zeng J, Cui PJ, Zhang T, Sun ZK, Ren RJ, Deng YL, Xu W, Wang Y, Chen SD. Economic Impact of Dementia in Developing Countries: An Evaluation of Alzheimer-Type Dementia in Shanghai, China. Journal of Alzheimer’s Disease. 2008;15(1):109–15.CrossRefGoogle Scholar
  28. Wang J, Xiao LD, He GP, De Bellis A. Family caregiver challenges in dementia care in a country with undeveloped dementia services. J Adv Nurs. 2014;70(6):1369–80.CrossRefGoogle Scholar
  29. Williams A. Health and Economics. Palgrave Macmillan, London. 1987.Google Scholar
  30. Wong YC, Leung J. Long-term care in China: issues and prospects. J Gerontol Soc Work. 2012; 55(7):570–86.CrossRefGoogle Scholar
  31. Wu C, Gao L, Chen S, Dong H. Care services for elderly people with dementia in rural China: a case study. Bull World Health Organ. 2016;94(3):167–73.CrossRefGoogle Scholar
  32. Yang Z, Lin PJ, Levey A. Monetary costs of dementia in the United States. N Engl J Med. 2013; 369(5):489.CrossRefGoogle Scholar
  33. Zencir M, Kuzu N, Beser NG, Ergin A, Catak B, Sahiner T. Cost of Alzheimer’s disease in a developing country setting. Int J Geriatr Psychiatry. 2005;20(7):616–22.CrossRefGoogle Scholar
  34. Zhang Y, Xu Y, Nie H, Lei T, Wu Y, Zhang L, Zhang M. Prevalence of dementia and major dementia subtypes in the Chinese populations: a meta-analysis of dementia prevalence surveys, 1980–2010. J Clin Neurosci. 2012;19(10):1333–7.CrossRefGoogle Scholar
  35. Zhang H, Loi SM, Zhou S, Zhao M, Lv X, Wang J, Wang X, Lautenschlager N, Yu X, Wang H. Dementia literacy among community-dwelling older adults in urban China: a cross-sectional study. Front Public Health. 2017;5:124.CrossRefGoogle Scholar
  36. Zhu CW, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, Sano M, Stern Y. Clinical features associated with costs in early AD: baseline data from the Predictors Study. Neurology. 2006; 66(7):1021–8.CrossRefGoogle Scholar
  37. Zou YM, Liu J, Tian ZY, Lu D, Zhou YY. Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China. Neuropsychiatr Dis Treat. 2015;11:1467–72.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Neurology and Neuroscience InstituteRuijin Hospital affiliated to Shanghai Jiao Tong University School of MedicineShanghaiP.R. China

Section editors and affiliations

  • Peter Riederer
    • 1
  1. 1.University Hospital, Center for Mental Health, Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University WuerzburgWuerzburgGermany

Personalised recommendations